BioCentury
ARTICLE | Company News

Catalyst, Isu Abxis partner for Catalyst's Factor IX

October 9, 2013 11:42 PM UTC

Catalyst Biosciences Inc. (South San Francisco, Calif.) and Isu Abxis Co. Ltd. (KOSDAQ:086890) partnered to develop Catalyst's FIX-NG (CB 2679d) through Phase I testing to prevent and treat bleeding in hemophilia B patients. The recombinant Factor IX protein is in preclinical testing, with Phase I slated to start in 2015. Isu Abxis will fund and develop FIX-NG through Phase I testing and will receive an undisclosed percentage of potential revenue. Isu Abxis also has an exclusive option to license rights to commercialize FIX-NG in South Korea.

Catalyst will receive an undisclosed upfront payment and is eligible for undisclosed milestones through the end of Phase I. Catalyst is responsible for development of FIX-NG after Phase I testing. ...